- Male or female subjects aged 18 years or older
- Isolation of a resistant gram-negative pathogen, eg, Enterobacter species,
Acinetobacter baumannii, Klebsiella pneumoniae, or other resistant gram-negative
pathogens, alone or as 1 isolate of a polymicrobial infection
- Resistant gram-negative organisms are defined by the likely presence of ESBL or
related mechanisms which limit the therapeutic alternatives for the treatment of
complicated infections
- Subjects with any concomitant condition or taking any concomitant medication that, in
the opinion of the investigator, could preclude an evaluation of a response or make it
unlikely that the contemplated course of therapy or follow-up assessment will be
completed or that will substantially increase the risk associated with the subject's
participation in this study
- Anticipated length of antibiotic therapy
- Known or suspected hypersensitivity to tigecycline or other compounds related to this
class of antibacterial agents (eg, tetracyclines, minocycline, doxycycline)